- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 237/00 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
Patent holdings for IPC class C07D 237/00
Total number of patents in this class: 84
10-year publication summary
|
6
|
0
|
6
|
2
|
5
|
2
|
2
|
3
|
2
|
2
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Merck Sharp & Dohme Corp. | 2190 |
3 |
| Boehringer Ingelheim International GmbH | 4640 |
3 |
| JPMorgan Chase Bank, National Association | 8586 |
3 |
| ChemoCentryx, Inc. | 383 |
3 |
| Jiangsu Hengrui Medicine Co., Ltd. | 708 |
3 |
| Novartis AG | 10721 |
2 |
| Bristol-myers Squibb Company | 4849 |
2 |
| Sumitomo Chemical Company, Limited | 9079 |
2 |
| Northwestern University | 3418 |
2 |
| Mirati Therapeutics, Inc. | 259 |
2 |
| Senhwa Biosciences, Inc. | 38 |
2 |
| Sichuan Huiyu Pharmaceutical Co., Ltd. | 31 |
2 |
| Vanderbilt University | 1919 |
2 |
| Pharmacosmos A/S | 65 |
2 |
| Pharmacosmos Holding A/S | 202 |
2 |
| Alto Neuroscience, Inc. | 50 |
2 |
| Merck Sharp & Dohme LLC | 3753 |
2 |
| Sichuan Huiyu Seacross Pharmaceutical Technology Co., Ltd. | 23 |
2 |
| Hoffmann-La Roche Inc. | 3478 |
1 |
| Merck Patent GmbH | 5767 |
1 |
| Other owners | 41 |